Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of CTP-656 in Healthy Males
NCT02680249Phase 1Completed
- Sponsor
- Concert Pharmaceuticals
- Start
- Feb 2016
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of deutivacaftor in cystic fibrosis (CF) (3 arms), sponsored by Concert Pharmaceuticals. Primary endpoint: Pharmacokinetics of CTP-656 at 96 hours. Started Feb 2016; status: completed.
02
Drugs
deutivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02680249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02680249.